An Update on Inhibitors of Human 14 kDa Type II s PLA2 in Development

Author: Springer, D.M.

Source: Current Pharmaceutical Design, Volume 7, Number 3, 1 February 2001 , pp. 181-198(18)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Recent progress in the development of inhibitors of human Type II s PLA2 as potential anti inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY 315920 (S 5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY 315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s PLA2 that have been reported to be in late stage development.

Keywords: Phospholipases A2; Arachidonic acid; Lipoxygenase enzymes; anti inflammatory responses; Phosphatidylcholine micelle; Transgenic mice; Indoxam blocked; carrageenan induced; Phthalic anhydride; Analysis and Speculatin

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013398275

Publication date: 2001-02-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.